BioCentury
ARTICLE | Company News

Kite, NCI expand cancer immunotherapy collaboration

March 3, 2015 1:42 AM UTC

Kite Pharma Inc. (NASDAQ:KITE) and NIH's National Cancer Institute expanded a 2012 Cooperative Research and Development Agreement (CRADA) to include immunotherapies against neo-antigens and additional undisclosed T cell receptor ( TCR) and chimeric antigen receptor (CAR) T cell candidates targeting solid tumors.

Under the amended deal, the partners will develop methods to rapidly identify candidates targeting neo-antigens and optimize manufacturing of the candidates. Neo-antigens are tumor-specific antigens that arise as tumors accumulate genetic mutations. ...